Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | MET | P08581 | 1/20 | 0.48 |
| ▸ | RET | P07949 | 2/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.45 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | BCL2 | P10415 | 1/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9343184 | 0.91 | LMNA (0.63) | LMNAALDH1A1MAPTMETRET | |
| SCHEMBL16270620 | 0.86 | MAPT (0.71) | LMNAALDH1A1MAPTMETPDK2 | |
| SCHEMBL29858317 | 0.86 | MAPT (0.71) | LMNAALDH1A1MAPTMETPDK2 | |
| SCHEMBL5216622 | 0.84 | MAPT (0.68) | LMNAALDH1A1MAPTMETPDK2 | |
| SCHEMBL16665290 | 0.84 | ALDH1A1 (0.68) | LMNAALDH1A1MAPTMETPDK2 | |
| SCHEMBL28978026 | 0.83 | MAPT (0.67) | LMNAALDH1A1MAPTMETPDK2 | |
| SCHEMBL16270621 | 0.83 | MAPT (0.70) | LMNAALDH1A1MAPTMETPDK2 | |
| SCHEMBL20339075 | 0.83 | MAPT (0.67) | LMNAALDH1A1MAPTMETPDK2 | |
| SCHEMBL29355899 | 0.83 | MAPT (0.67) | LMNAALDH1A1MAPTMETPDK2 | |
| SCHEMBL20352127 | 0.83 | MAPT (0.67) | LMNAALDH1A1MAPTMETPDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073900-B2 | Dihydroquinone derivatives of piperidine and piperazine | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2015-07-07 | — | — | US | disclosed |
| US-20150094467-A1 | DIHYDROQUINONE DERIVATIVES OF PIPERIDINE AND PIPERAZINE | KING ABDULAZIZ CITY FOR SCIENCE AND TECHNOLOGY (SA) | 2015-04-02 | — | — | US | disclosed |
| US-8168645-B2 | Arylsulfonamide compounds | GENENTECH, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168645-B2 | Arylsulfonamide compounds | GENENTECH, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20110098305-A1 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | BAELL JONATHAN BAYLDON | 2011-04-28 | — | — | US | disclosed |
| US-20110098305-A1 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | BAELL JONATHAN BAYLDON | 2011-04-28 | — | — | US | disclosed |
| EP-2279174-A2 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Genentech, Inc. (US) | 2011-02-02 | — | — | EP | disclosed |
| US-20100056517-A1 | ARYLSULFONAMIDE COMPOUNDS | GENENTECH, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056517-A1 | ARYLSULFONAMIDE COMPOUNDS | GENENTECH, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| WO-2009143246-A2 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056517-A1 | ARYLSULFONAMIDE COMPOUNDS | BCL2A1, BCL2, BAX | LMNA 792/4885ALDH1A1 4286/4885MAPT 4408/4885 |
| US-20110098305-A1 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | BAX, API5, BCL2 | LMNA 325/4885ALDH1A1 4380/4885MAPT 4404/4885 |
| US-20150094467-A1 | DIHYDROQUINONE DERIVATIVES OF PIPERIDINE AND PIPERAZINE | HTR2C, HTR5A, HTR2A | LMNA 1586/4885ALDH1A1 209/4885MAPT 2861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.